Any Stage of Lung Cancer (Any Histotype)SPECTAlungNCT02214134
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
An observational study of Any Stage of Lung Cancer (Any Histotype) and Any Stage of Malignant Pleural Mesothelioma, run by European Organisation for Research and Treatment of Cancer - EORTC at 18 sites in 9 countries.
Trial summary
SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. The thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma, Any Stage of Any Thymic Malignancy
- What is being tested?
- Tumour markers testing
- How many people
- 539 participants
- Where
- 18 sitesin 9 countries
- Study dates
- 22 May 2015to 12 May 2021
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at any stage.
Who may be able to join
- Pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at any stage;
- Mandatory availability of adequate Human Biological Material (HBM): FFPE tissue sample from the primary tumor, recurrent tumor, metastasis, obtained at the time of primary surgery or biopsy; minimal amount requested is detailed in the HBM guidelines; inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional;
- Centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening;
- Age ≥ 18 years;
- At least three months life-expectancy;
- Written informed consent according to ICH/GCP and national/local regulations.
Who cannot join
- Any active malignancy, except pT1-2 prostatic cancer Gleason score < 6, non melanomatous skin cancer or carcinoma in situ of the cervix, in the 5 years before study entry;
- Active hepatitis B/C or HIV;
- Any secondary malignancy;
- Any severe organ dysfunction or other comorbidities that may prevent the inclusion into clinical trials.
Trial locations and contacts
18 sites in 9 countries.
18 sites in 9 countries
France4 sites
CHU de Lyon - Hopital Louis Pradel
Lyon, 69394
Assistance Publique - Hopitaux de Marseille - Hopital Nord
Marseille, 13015
CHU Toulouse - Hopital Larrey
Toulouse, 31059
Gustave Roussy Cancer Campus
Villejuif, 94805
Belgium3 sites
Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels, 1000
Universitair Ziekenhuis Antwerpen
Edegem
U.Z. Leuven - Campus Gasthuisberg
Leuven, 3000
United Kingdom3 sites
Royal Marsden Hospital - Kingston Hospital
Kingston upon Thames, KT2 7QB
Royal Marsden Hospital - Chelsea, London
London, SW3 6JJ
Royal Marsden Hospital - Sutton, Surrey
Sutton, SM2 5PT
Spain2 sites
Hospital General Vall D'Hebron
Barcelona, 08035
Hospital Universitario 12 De Octubre
Madrid, ES 28041
Switzerland2 sites
Centre Hospitalier Universitaire Vaudois - Lausanne
Lausanne, CH 1011
Centre Hospitalier Universitaire Vaudois - Lausanne
Lausanne, CH1011
About this study
SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. The thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Once the molecular characteristics are identified, there might be the possibility to offer these patients access to targeted clinical trials.
- Conditions
- Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma, Any Stage of Any Thymic Malignancy
- Being tested
- Tumour markers testing
- Keywords
- Lung cancer, Malignant pleural mesothelioma, Thymic malignancy, Biomarkers, Screening
- Medical subject headings
- Lung Neoplasms, Mesothelioma, Malignant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tumour markers testingGenetic
| Study group | Role | What they receive |
|---|---|---|
| Lung cancer | Patients with diagnosis of lung cancer at any stage Receives: Genetic: Tumour markers testing | |
| Malignant pleural mesothelioma | Patients with diagnosis of malignant pleural mesothelioma at any stage Receives: Genetic: Tumour markers testing | |
| Thymic malignancy | Patients with diagnosis of thymic malignancy at any stage Receives: Genetic: Tumour markers testing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients with thoracic malignancy (lung cancer, MPM and thymic malignancies) screened and efficiently allocated to biomarker-driven clinical trials.
Measured: 5 years
Secondary outcomes (2)
Number of patients for whom the description of the biomarkers and correlation to clinical/pathological characteristics can be performed.
Measured: 5 years
Number of exploratory/future research projects developped
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2014 (estimated)
- Study start22 May 2015
- Primary completion22 Oct 2020
- Study completion12 May 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Any Stage of Lung Cancer (Any Histotype)Studies of the same condition, open and under way.
- More trials run by European Organisation for Research and Treatment of Cancer - EORTCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 539 participants (actual)
- Target duration
- 5 Years
Sponsor and investigators
- Sponsor type
- Research network
- Collaborators
- ETOP IBCSG Partners Foundation
- Responsible party
- Sponsor
- Investigators
- Benjamin Besse, MD, PhD, Study chair, Gustave Roussy, Cancer Campus, Grand Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02214134
- Sponsor's protocol ID
- EORTC-1335-LCG-PBG
- Acronym
- SPECTAlung
- Status last verified
- Aug 2025
- First submitted
- 7 Aug 2014
- Last updated
- 17 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
- ClinicalTrials.gov ID
- NCT02214134
- Acronym / sponsor ID
- SPECTAlung / EORTC-1335-LCG-PBG
- Conditions
- Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma, Any Stage of Any Thymic Malignancy
- Keywords
- Lung cancer, Malignant pleural mesothelioma, Thymic malignancy, Biomarkers, Screening
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 539 participants (actual)
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Collaborators
- ETOP IBCSG Partners Foundation
- Study start
- 22 May 2015 (actual)
- Primary completion
- 22 Oct 2020 (actual)
- Study completion
- 12 May 2021 (actual)
- First posted
- 12 Aug 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. The thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Once the molecular characteristics are identified, there might be the possibility to offer these patients access to targeted clinical trials.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Lung cancer | – | Genetic: Tumour markers testingPatients with diagnosis of lung cancer at any stage |
| Malignant pleural mesothelioma | – | Genetic: Tumour markers testingPatients with diagnosis of malignant pleural mesothelioma at any stage |
| Thymic malignancy | – | Genetic: Tumour markers testingPatients with diagnosis of thymic malignancy at any stage |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at any stage.
Key inclusion criteria (6 listed)
- Pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at any stage;
- Mandatory availability of adequate Human Biological Material (HBM): FFPE tissue sample from the primary tumor, recurrent tumor, metastasis, obtained at the time of primary surgery or biopsy; minimal amount requested is detailed in the HBM guidelines; inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional;
- Centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening;
- Age ≥ 18 years;
- At least three months life-expectancy;
Key exclusion criteria (4 listed)
- Any active malignancy, except pT1-2 prostatic cancer Gleason score < 6, non melanomatous skin cancer or carcinoma in situ of the cervix, in the 5 years before study entry;
- Active hepatitis B/C or HIV;
- Any secondary malignancy;
- Any severe organ dysfunction or other comorbidities that may prevent the inclusion into clinical trials.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tumour markers testing | Genetic | Lung cancer, Malignant pleural mesothelioma, Thymic malignancy |
Primary outcome
Number of patients with thoracic malignancy (lung cancer, MPM and thymic malignancies) screened and efficiently allocated to biomarker-driven clinical trials.
Time frame: 5 years
2 secondary outcomes
Number of patients for whom the description of the biomarkers and correlation to clinical/pathological characteristics can be performed.
Time frame: 5 years
Number of exploratory/future research projects developped
Time frame: 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2025.
Related trials for Any Stage of Lung Cancer (Any Histotype)
Active, not recruitingPhase 1/2
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
RecruitingPhase 2
Phase II Trial of Lung Chemoemobolization
Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm
RecruitingPhase 1/2
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benjamin Besse, MD, PhD study chair
Gustave Roussy, Cancer Campus, Grand Paris
18 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Any Stage of Lung Cancer (Any Histotype) and Any Stage of Malignant Pleural Mesothelioma, run by European Organisation for Research and Treatment of Cancer - EORTC at 18 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 18 sites in France, Belgium, United Kingdom, Spain, Switzerland and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients with thoracic malignancy (lung cancer, MPM and thymic malignancies) screened and efficiently allocated to biomarker-driven clinical trials. (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2025.